Nonalcoholic fatty liver (NAFLD) is one of the most common liver disorders worldwide which could result in liver cirrhosis and its complication. This randomized clinical trial is designed to evaluate the efficacy of Epigallocatechin gallate (EGCG, green tea) on the serum levels of liver transaminases and inflammatory markers among NAFLD patients.

In this clinical trial, patients who diagnosed with NAFLD during 3months period included and randomly divided into 2 groups: group A (intervention group) who received 390mg of green tea extract for 3 months and group B who received placebo as control group. The serum levels of liver transaminases, blood sugar, serum TG and cholesterol and inflammatory markers measured before and after intervention and the results of collected DATA compared between2 groups.

Overall 58 patients included (30 patients in group A and 28 cases as control group). At the end of the study, the green tea group showed a significant reduction in liver enzymes (aspartate aminotransferase (before45.76 ± 18.63, after 33.79 ± 12.27, P<0.001) and alanine aminotransferase (before 77.1 ± 35.87, after 53.8 ± 18.26, P <0.001)) compared with the placebo group. The serum levels of triglycerides, total cholesterol and LDL had also a decrease among intervention group as compared to baseline while these changes were not significant in comparison with placebo group (P = 0.75, 0.366 and 0.253 respectively). In addition, no significant changes occurred in sonographic grades of NAFLD among two groups.

green tea has a positive effect of the serum levels of liver transaminases among NAFLD and could be a therapeutic approach or recommendable supplement for this group of patients.